Cohance Lifesciences, backed by Advent International, has announced the appointment of Umang Vohra as its new chairman and group CEO, effective May 1, 2026. Vohra, who has over a decade of experience at Cipla, is expected to lead the company through its current growth challenges and regulatory scrutiny. His predecessor, Vivek Sharma, will step down on April 30, 2026, but will remain as a special advisor for nine months to ensure a smooth transition. Following the announcement, Cohance's shares rose by nearly 20%, closing at ₹432.70 per share on the Bombay Stock Exchange (BSE). The leadership change aims to strengthen execution and customer relationships as the company seeks to expand its presence in the contract development and manufacturing (CDMO) sector. Additionally, the board approved the Cohance Lifesciences Employee Stock Option Plan (ESOP) 2026, which allows for the granting of up to 25.9 million stock options, representing about 6.25% of the company's fully diluted equity capital.